PET Imaging for Response Assessment in Lymphoma: Potential and Limitations
Section snippets
Clinical background
HL and NHL are the most common hematologic malignancies in the United States; they account for 4% to 5% of all new cancer cases and are the fifth leading cause of cancer death in the United States.
Among HL, nodular sclerosis is the most common subtype in the United States and Western Europe, followed by mixed cellularity phenotype, lymphocyte-predominant subtype, and lymphocyte-depleted subtype. The international prognostic score is used for risk stratification.1 Treatment decisions for
Positron emission tomography imaging
FDG-PET is now widely used for the staging, restaging, and detection of recurrence in many patients with HL and NHL. It is also increasingly used for monitoring the response to chemotherapy in these patients. For meaningful clinical use, the specific lymphoma entity has to be FDG-avid. Although this information may be inferred from past studies,23, 24 it is clearly desirable to obtain a baseline scan to assess the extent of disease and to establish the degree and intensity of FDG uptake in
Background
Historically, imaging studies were obtained at baseline and after completion of therapy, for the purpose of staging and restaging. Investigators realized increasingly that a lack of complete normalization on structural imaging, either conventional radiograms53, 54 or CT,55 did not necessarily indicate the presence of residual viable tumor tissue. This led to the introduction of a category “complete response, unconfirmed” in the 1999 lymphoma response criteria.55 That is, clinicians presumed
Background
Early response assessment, although much en vogue nowadays, is not new. As early as 1986, Armitage and colleagues71 reported that “rapidly responding patients with DLBCL have more durable remissions.” They used conventional response criteria and chest radiograph and abdominal CT. With the advent of functional imaging, Front and colleagues72 used 67gallium scintigraphy for similar purpose and in 1999 published that a “negative test after one cycle of chemotherapy is a good early predictor of
Pediatric patients
In children and adolescents, HL and Burkitt's lymphoma, lymphoblastic, and DLBCL are the most common histopathologic subtypes. These tumors are generally FDG-avid. These considerations should also apply to PET response assessment in pediatric patients, but this needs to be proved in prospective studies.
Imaging with 18F fluorothymidine
This article is entirely focused on PET imaging with FDG. Among the many other PET radiotracers, the proliferation marker 18F fluorothymidine (FLT) seems particularly promising for treatment monitoring.84 FLT uptake depends on the activity of nucleoside transporters and the activity of the enzyme thymidine kinase 1.85 Thymidine kinase 1 activity correlates well with other indicators of cellular proliferation, and tumor FLT uptake correlates with the tissue proliferation marker ki-67.86 In
Open questions
Among several open questions regarding the use of FDG-PET in lymphoma response assessment, Box 2 offers some that may be of particular interest to oncologists and imaging physicians.
Summary
FDG-PET is currently the most accurate tool for the assessment of treatment response and prognosis in lymphoma; it is certainly more accurate than structural imaging or clinical indices. Unfortunately, many published studies suffer from suboptimal methodology and incomplete data reporting. In general, the data seem more consistent in HL than in aggressive NHL. A negative PET excludes residual disease with reasonably high certainty. In contrast, positive PET findings should always be confirmed
References (88)
- et al.
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
Blood
(2004) - et al.
International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades
Blood
(1995) - et al.
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Blood
(2003) - et al.
Rituximab plus CHOP (R-CHOP) overcomes bcl-2–associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
Blood
(2003) - et al.
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
Lancet Oncol
(2008) - et al.
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Lancet Oncol
(2006) - et al.
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL
Blood
(2004) - et al.
Utility of FDG-PET scanning in lymphoma by WHO classification
Blood
(2003) - et al.
Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma
Mol Imaging Biol
(2004) Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma
Radiol Clin North Am
(2007)